IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: A longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment

Transplant International

Volumn 24, Issue 9, 2011, Pages 892-903

  Hinrichs, Carl ^a   Wendland, Sylke ^a   Zimmermann, Heiner ^a   Eurich, Dennis ^a   Neuhaus, Ruth ^a   Schlattmann, Peter ^b   Babel, Nina ^a,d   Riess, Hanno ^a   Gärtner, Barbara ^c   Anagnostopoulos, Ioannis ^a   Reinke, Petra ^a,d   Trappe, Ralf Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Berlin Brandenburg Center for Regenerative Therapies   (Germany)

Author keywords

cytotoxic T cells; immune monitoring; immunosuppression; interleukin 10; interleukin 6; post transplant lymphoproliferative disorders; treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MALE; PATHOGENESIS; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051695525     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01282.x     Document Type: Article

References (35)

1. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524.
2. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851.
3. Caillard S, Pencreach E, Braun L, et al. Simultaneous development of lymphoma in recipients of renal transplants from a single donor: donor origin confirmed by human leukocyte antigen staining and microsatellite analysis. Transplantation 2005; 79: 79.
4. Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008; 86: 215.
5. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
6. Swinnen LJ,. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000; 11 (Suppl. 1): 45.
7. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901.
8. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2006; 107: 3053.
9. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92: 1489.
10. Trappe R, Choquet S, Oertel SHK, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD-moving forward to a first standard of care: results from a prospective International Multicenter Trial. ASH Annual Meeting Abstracts 2009; 114: 100.
11. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052.
12. Gottschalk S, Rooney CM, Heslop HE,. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29.
13. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101.
14. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL,. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993; 91: 2806.
15. Swinnen LJ, Fisher RI,. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertens 1993; 2: 670.
16. Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK,. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876.
17. Haddad E, Paczesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001; 97: 1590.
18. Nalesnik MA, Starzl TE,. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci 1994; 4: 61.
19. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999; 1: 3.
20. Babel N, Vergopoulos A, Trappe RU, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 2007; 84: 387.
21. Muti G, Klersy C, Baldanti F, et al. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 2003; 122: 927.
22. Muti G, Mancini V, Ravelli E, Morra E,. Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders. Leuk Lymphoma 2005; 46: 1397.
23. Baiocchi OC, Colleoni GW, Caballero OL, et al. Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort. Leuk Lymphoma 2005; 46: 533.
24. Nepomuceno RR, Snow AL, Robert Beatty P, Krams SM, Martinez OM,. Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder. Transplantation 2002; 74: 396.
25. Trappe R, Oertel SH, Choquet S, LeBlond V, Papp-Vary M, Riess H,. Sequential treatment with the anti-CD 20 antibody rituximab and CHOP + GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): first results of a multicenter phase II study. Blood (ASH Annual Meeting Abstracts) 2005; 106: 932.
26. Trappe R, Choquet S, Oertel S, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD-a new standard in therapy? Blood 2007; 110: 390.
27. Wolfinger R, Tobias R, Sall J,. Computing Gaussian likelihoods and their derivatives for general linear mixed models. SIAM J Sci Comput 1994; 15: 16.
28. Fassone L, Gaidano G, Ariatti C, et al. The role of cytokines in the pathogenesis and management of AIDS-related lymphomas. Leuk Lymphoma 2000; 38: 481.
29. Ruff KR, Puetter A, Levy LS,. Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer 2007; 7: 35.
30. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27.
31. Yun AJ, Lee PY,. The link between T helper balance and lymphoproliferative disease. Med Hypotheses 2005; 65: 587.
32. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007; 17: 203.
33. Khatri VP, Baiocchi RA, Peng R, et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 1999; 163: 500.
34. Kuzushima K, Kimura H, Hoshino Y, et al. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. J Infect Dis 2000; 182: 937.
35. Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399.